Biogen proposes to buy remaining stake in Sage in $442 million deal - WSAU
Sage Therapeutics confirms $7.22 per share acquisition proposal from Biogen - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation - AccessWire
Biogen proposes to buy remaining stake in Sage in $442 million deal - MSN
Biogen proposes to buy remaining stake in Sage in $442 million deal - MSN
Sage Therapeutics (NASDAQ:SAGE) Shares Cross Below 200-Day Moving Average - Here's Why - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Stock Passes Below 200 Day Moving Average - Here's Why - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Share Price Passes Below 200 Day Moving Average - What's Next? - MarketBeat
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen - Business Wire
Sage Therapeutics Receives Surprise $7.22 Per Share Acquisition Offer from Biogen - StockTitan

Pages